Anti-cancer therapy with EGFR inhibitors: Factors of prognostic and predictive significance

Annals of Oncology

Volumn 17, Issue SUPPL. 2, 2006, Pages

  Metro, G ^a   Finocchiaro, G ^a   Cappuzzo, Federico ^a  

^a BELLARIA HOSPITAL   (Italy)

Author keywords

EGFR; Non small cell lung cancer; Tyrosine kinase inhibitor

Indexed keywords

CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; IRINOTECAN; MONOCLONAL ANTIBODY; PANITUMUMAB; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PLACEBO; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; CORRELATION ANALYSIS; DIARRHEA; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; ENZYME INHIBITION; GENE MUTATION; GLIOMA; HUMAN; LUNG CARCINOGENESIS; LUNG NON SMALL CELL CANCER; OUTCOMES RESEARCH; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; RISK FACTOR; SKIN TOXICITY; SMOKING HABIT;

EID: 33645818557     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdj920     Document Type: Article

References (46)

1. Mendelsohn J, Baselga J. The EGF receptor family as targets for cancer therapy. Oncogene 2000; 19: 6550-6565.
2. Woodburn JR. The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol Ther 1999; 82: 241-250.
3. Fukuoka M, Yano S, Giaccone G et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 2003; 21: 2237-2246.
4. Kris MG, Natale RB, Herbst RS et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: A randomized trial. J Am Med Assoc 2003; 290: 2149-2158.
5. Perez-Soler R, Chachoua A, Hammond L et al. Determinants of tumor response and survival with erlotinib in patients with non-small cell lung cancer (NSCLC). J Clin Oncol 2004; 22: 3238-3247.
6. Giaccone G, Herbst RS, Manegold C et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: A phase III trial - INTACT 1. J Clin Oncol 2004; 22: 777-784.
7. Gatzemeier U, Pluzanska A, Szczesna A et al. Results of a phase III trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine (GC) chemotherapy in advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2004; 22: 617s (Abstr no. 7010).
8. Herbst RS, Giaccone G, Schiller JH et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: A phase III trial - INTACT 2. J Clin Oncol 2004; 22: 785-794.
9. Herbst RS, Prager D, Hermann R et al. TRIBUTE - A phase III trial of erlotinib hydochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2005; 23: 5892-5899.
10. Shepherd FA, Pereira J, Ciuleanu TE et al. Erlotinib in previously treated non-small cell lung cancer. N Engl J Med 2005; 353: 123-132.
11. Thatcher N, Chang A, Parikh P et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: Results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005; 366: 1527-1537.
12. Miller VA, Kris MG, Shah N et al. Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. J Clin Oncol 2004; 22: 1103-1109.
13. Kim YH, Ishii G, Goto K et al. Dominant papillary subtype is a significant predictor of the response to gefitinib in adenocarcinoma of the lung. Clin Cancer Res 2004; 10: 7311-7317.
14. Thienelt CD, Bunn PA Jr, Hanna N et al. Multicenter Phase I/II Study of Cetuximab With Paclitaxel and Carboplatin in Untreated Patients With Stage IV Non-Small-Cell Lung Cancer. J Clin Oncol 2005; 23: 8786-8793.
15. Janne PA, Gurubhagavatula S, Yeap BY et al. Outcomes of patients with advanced non-small cell lung cancer treated with gefitinib (ZD1839, "Iressa") on an expanded access study. Lung Cancer 2004; 44: 221-230.
16. Mohamed MK, Ramalingam S, Lin Y et al. Skin rash and good performance status predict improved survival with gefitinib in patients with advanced non-small cell lung cancer. Ann Oncol 2005; 16: 780-785.
17. Perez-Soler R. Can rash associated with HER1/EGFR inhibition be used as a marker of treatment outcome? Oncology 2003; 17: 23-28.
18. Lynch TJ, Bell DW, Sordella R et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350: 2129-2139.
19. Paez JG, Janne PA, Lee JC et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304: 1497-1500.
20. Pao W, Miller V, Zakowski M et al. EGF receptor gene mutations are common in lung cancer from "never-smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci 2004; 101: 13306-13311.
21. Pao W, Wang TY, Riely GJ et al. KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib. PLoS Med 2005; 2: E17.
22. Shigematsu H, Lin L, Takahashi T et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 2005; 97: 339-346.
23. Cappuzzo F, Hirsch FR, Rossi E et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small cell lung cancer. J Natl Cancer Inst 2005; 97: 643-655.
24. Tsao MS, Sakurada A, Cutz JC et al. Erlotinib in lung cancer - molecular and clinical predictors of outcome. N Engl J Med 2005; 353: 133-144.
25. Han SW, Kim TY, Hwang PG, et al. Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol 2005; 23: 2493-2501.
26. Bell DW, Lynch TJ, Haserlat SM et al. Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. J Clin Oncol 2005; 23: 8081-8092.
27. Eberhard DA, Johnson BE, Amler LC et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 2005; 23: 5900-5909.
28. Hirsch FR, Varella-Garcia M, Bunn PA Jr. et al. Epidermal growth factor receptor in non-small-cell lung carcinomas: Correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol 2003; 21: 3798-3807.
29. Hirsch FR, Varella-Garcia M, McCoy J et al. Increased epidermal growth factor receptor gene copy number detected by Fluorescence in situ Hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: A Southwest Oncology Group Study. J Clin Oncol 2005; 23: 6838-6845.
30. Hirsch FR, Varella-Garcia M, Bunn PA et al. Molecular analysis of EGFR gene copy number, EGFR expression and Akt activation status in advanced non-small-cell lung cancer (aNSCLC) treated with gefitinib or placebo (ISEL trial). AACR-NCI-EORTC 2005; 124 (abstr A268).
31. Bailey R, Kris M, Wolf M, et al. Gefitinib ('Iressa', ZD1839) monotherapy for pretreated advanced non-small-cell lung cancer in IDEAL 1 and 2: Tumor response in not clinically relevantly predictable from tumor EGFR membrane staining alone. Lung Cancer 2003; 41: S71 (abstr 0-242).
32. Cappuzzo F, Varella-Garcia M, Domenichini I, et al. Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal-growth factor receptor positive non-small-cell lung cancer patients. J Clin Oncol 2005; 23: 5007-5018.
33. Onn A, Correa AM, Gilcrease M et al. Synchronous overexpression of epidermal growth factor receptor and HER2-neu protein is a predictor of poor outcome in patients with stage I non-small cell lung cancer. Clin Cancer Res 2004; 10: 136-143.
34. Moasser MM, Basso A, Averbuch SD Rosen N. The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signalling and suppresses the growth of HER2-overexpressiog tumor cells. Cancer Res 2001; 61: 7184-7188.
35. David O, Jett J, LeBeau H et al. Phospho-Akt overexpression in non-small cell lung cancer confers significant stage-independent survival disadvantage. Clin Cancer Res 2004; 10: 6865-6871.
36. Cappuzzo F, Magrini E, Ceresoli GL et al. AKT phosphorylation and gefitinib efficacy in patients with advanced Non-Small Cell Lung Cancer. J Natl Cancer Inst 2004; 96: 1133-1141.
37. Ono M, Hirata A, Kometani T et al. Sensitivity to gefitinib (Iressa, ZD1839) in non-small cell lung cancer cell lines correlates with dependence on the epidermal growth factor (EGO receptor/extracellular signal-regulated kinase 1/2 and EGF receptor/Akt pathway for proliferation. Mol Cancer Ther 2004; 3: 465-472.
38. Rich JN Reardon DA, Peery T, Phase II trial of gefitinib in recurrent glioblastoma, J Clin Oncol 2004; 22: 133-142.
39. Haas-Kogan DA, Prados MD, Tihan T et al. Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib. J Natl Cancer Inst 2005; 97: 880-887.
40. Mellinghoff IK, Wang MY, Vivanco I, Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med. 2005; 353: 2012-2024.
41. Barber TD, Vogelstein B, Kinzler KW, Velculescu VE. Somatic mutations of EGFR in colorectal cancers and glioblastomas. N Engl J Med. 2004; 351: 2883.
42. Frederick L, Wang XY, Eley G, James CD. Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas. Cancer Res. 2000; 60: 1383-1387.
43. Cunningham D, Humblet Y, Siena S et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351: 337-345.
44. Chung KY, Shia J, Kemeny NE et al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor J Clin Oncol 2005; 23: 1803-1810.
45. Moroni M, Veronese S, Benvenuti S et al. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: A cohort study. Lancet Oncol 2005; 6: 279-286.
46. Mukohara T, Engelman JA, Hanna NH et al. Differential effect of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations. J Natl Cancer Inst 2005; 97: 1185-1194.